Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide

Product Details
Customization: Available
Powder: Yes
Customized: Non-Customized
Manufacturer/Factory, Trading Company

360° Virtual Tour

Diamond Member Since 2016

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Importers and Exporters
The supplier has import and export rights
Full Customization
The supplier provides full customization services
ODM Services
The supplier provides ODM services
Quality Assurance
The supplier provides quality assurance
to see all verified strength labels (17)
  • Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
  • Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
  • Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
  • Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
  • Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
  • Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
Find Similar Products
  • Overview
  • Product Description
  • Detailed Photos
Overview

Basic Info.

Model NO.
Livagen (Lys-Glu-Asp-Ala)
Certification
GMP, ISO 9001
Suitable for
Elderly, Children, Adult
State
Liquid
Purity
>98%
Transport Package
Al-Foil Bag
Specification
1bags
Trademark
HHD
Origin
China
Production Capacity
1000bags

Product Description

 
Product Description
Product name Livagen(Lys-Glu-Asp-Ala)
CAS No. N/A
MF C18H31N5O9
MW 461.47

 

Functions

It is stated that Livagen (Lys-Glu-Asp-Ala) is a weakly hydrolyzed peptide. Peptide hydrolases of small intestine do not hydrolyze Livagen even to a small extent. Under in vitro conditions Livagen reduces glycil-L-leucinedipeptidase activity in small intestine by 50%.Livagen induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes repressed due to age-related condensation of euchromatic regions in chromosomes. Our results indicate that Livagen causes de-heterochromatinization (activation) of chromatin, which is realized via modification of heterochromatin and heterochromatinized regions in chromosomes from old people.Livagen proved to be more efficient also as compared to well-known peptidase inhibitors such as puromycin, leupeptin, and D-PAM. The dose-inhibitory effect curves for Livagen and Epitalon were plotted; their IC50 equaled 20 and 500 microM, respectively.

Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide

Related products

Type Product Name Speafication Standard
Female hormones Progesterone 57-83-0 USP39
Estriol 50-27-1 USP41
Estrogen 56-53-1 USP41
Estradiol benzoate 50-50-0 USP
β-ESTRADIOL 50-28-2 USP39
Ethynyl estradiol 57-63-6 USP
Megestrol acetate 595-33-5 USP39
17a-Hydroxyprogesterone caproate 630-56-8 USP 
Oestradiol 17-heptanoate 4956-37-0 USP
Depofemin 313-06-4 USP37
Pregnenolone 145-13-1 USP
Levonorgestrel 797-63-7 USP
     
 
 
Other hot sales
Product name
CAS No.
β-Nicotinamide Mononucleotide (NMN)
1094-61-7
beta-Diphosphopyridine nucleotide (NAD)
53-84-9
Nicotinamide riboside chloride (NRC)
23111-00-4
Nicotinamide Ribose (NR)
1341-23-7
 
53-43
 
 
Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
Detailed Photos

 

Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
 

Extraction process:

Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide


 


Extraction workshop:

Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide

Storehouse:

Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
 
 
Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier